OKYO Pharma (STU:OK10) Research & Development: €-0.00 Mil (TTM As of Sep. 2025)


STU:OK10 OKYO Pharma Ltd STU:OK10
23 GF Score
Price €2.16
! 3 Warning Signs
View Full Analysis

What is OKYO Pharma Research & Development?

OKYO Pharma STU:OK10 23 Research & Development is €-0.00 Mil as of Sep. 2025. GuruFocus rates STU:OK10 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. OKYO Pharma's Research & Development for the six months ended in Sep. 2025 was €-0.04 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 was €-0.00 Mil.

OKYO Pharma  (STU:OK10) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

OKYO Pharma Research & Development Related Terms

OKYO Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for OKYO Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OKYO Pharma Research & Development Chart

OKYO Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 1.46 5.92 7.58 2.09

OKYO Pharma Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.31 3.35 2.00 0.04 -0.04
STU:OK10
23GF Score
OKYO Pharma Ltd STU:OK10
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OKYO Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €-0.00 Mil mean?
OKYO Pharma (STU:OK10) has a Research & Development of €-0.00 Mil as of Sep. 2025. Research and development expense is the total cost for research and development activities. View historical data on OKYO Pharma and its competitors.
Is OKYO Pharma's Research & Development too high?
OKYO Pharma's current Research & Development is €-0.00 Mil. Overall, OKYO Pharma has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does OKYO Pharma's Research & Development compare to ENTX and HRTX?
OKYO Pharma's Research & Development of €-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on OKYO Pharma and its competitors. OKYO Pharma's current Research & Development is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OKYO Pharma stock overvalued right now?
OKYO Pharma (STU:OK10) has a current Research & Development of €-0.00 Mil. The current Research & Development is €-0.00 Mil. OKYO Pharma's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For OKYO Pharma (STU:OK10), the current Research & Development is €-0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OKYO Pharma Business Description

Other Exchanges OKYO:USA
Address 14/15 Conduit Street, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
23GF Score

Get the complete analysis for STU:OK10

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.16
Price